logo-loader
RNS
Clinigen Group PLC

Clinigen Group plc - Grant of share options and PDMR notification

RNS Number : 6387V
Clinigen Group plc
04 December 2019
 

4 December 2019

 

 

Grant of share options and PDMR notification

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 December 2019, Nick Keher was granted share options over a total of 2,538 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under The Clinigen Group Sharesave Plan 2019. The option price for the shares is £7.09. The options are nil cost options intended to vest on 1 December 2022.

Director/PDMR

Number of share options granted

Total number of share options now held

 

Total number of ordinary shares held

Total number of ordinary shares (excluding share options) as % issued share capital

Nick Keher

2,538

136,889

 

3,900

Less than 0.01%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Nick Keher

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

213800OBIKGI2JYYS227

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Grant of Options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

2,538

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

2,538

Nil

 

f)

Date of the transaction

1 December 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Shaun Chilton, Group Chief Executive Officer

Nick Keher, Group Chief Financial Officer

Matt Parrish, Head of Investor Relations




Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Freddie Barnfield

 

 


RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Rozi Morris

Email: clinigen@instinctif.com

 

 

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

 

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

 

For more information on Clinigen, please visit www.clinigengroup.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHCKQDBCBDKPBK
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read